Eistland - eistneska - Ravimiamet

bristol-myers squibb gyogyszerkereskedelmi kft. - tsefepiim - süste-/infusioonilahuse pulber - 2000mg 1tk

Eistland - eistneska - Ravimiamet

mip pharma gmbh - tsefasoliin - süste-/infusioonilahuse pulber - 2g 5tk; 2g 1tk; 2g 10tk

Eistland - eistneska - Ravimiamet

abbvie sia - botulismitoksiin - süstelahuse pulber - 100ühik 6tk; 100ühik 3tk; 100ühik 1tk

Eistland - eistneska - Ravimiamet

sopharma ad - amikatsiin - süste-/infusioonilahus - 250mg 1ml 4ml 50tk; 250mg 1ml 2ml 100tk; 250mg 1ml 2ml 10tk

Eistland - eistneska - Ravimiamet

hospira uk limited - tsefasoliin - süste-/infusioonilahuse pulber - 2g 10ml 1tk; 2g 10ml 25tk; 2g 10ml 5tk; 2g 10ml 10tk

Eistland - eistneska - Ravimiamet

abbvie sia - botulismitoksiin - süstelahuse pulber - 50ühik 10tk; 50ühik 6tk

Eistland - eistneska - Ravimiamet

hospira uk limited - tsefasoliin - süste-/infusioonilahuse pulber - 1g 10ml 1tk; 1g 10ml 5tk

Eistland - eistneska - Ravimiamet

medochemie limited - tsefepiim - süste-/infusioonilahuse pulber - 1g 15ml 10tk; 1g 15ml 50tk

Evrópusambandið - eistneska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Evrópusambandið - eistneska - EMA (European Medicines Agency)

amivas ireland ltd - artesunate - malaaria - antiproteesid - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. tuleks arvesse võtta ametlikke juhiseid sobiva kasutamise kohta malaariavastasele ained.